WO1999052516A3 - Acylpeptide protease inhibitors to enhance cognitive function - Google Patents

Acylpeptide protease inhibitors to enhance cognitive function Download PDF

Info

Publication number
WO1999052516A3
WO1999052516A3 PCT/GB1999/001129 GB9901129W WO9952516A3 WO 1999052516 A3 WO1999052516 A3 WO 1999052516A3 GB 9901129 W GB9901129 W GB 9901129W WO 9952516 A3 WO9952516 A3 WO 9952516A3
Authority
WO
WIPO (PCT)
Prior art keywords
acylpeptide
protease inhibitors
cognitive function
enhance cognitive
medicament
Prior art date
Application number
PCT/GB1999/001129
Other languages
French (fr)
Other versions
WO1999052516A2 (en
Inventor
Paul Richards
Martin Johnson
David Ray
Original Assignee
Bayer Ag
Paul Richards
Martin Johnson
David Ray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Paul Richards, Martin Johnson, David Ray filed Critical Bayer Ag
Priority to AU34352/99A priority Critical patent/AU3435299A/en
Priority to CA002328360A priority patent/CA2328360A1/en
Priority to JP2000543126A priority patent/JP2002511407A/en
Priority to EP99915931A priority patent/EP1077689A1/en
Publication of WO1999052516A2 publication Critical patent/WO1999052516A2/en
Publication of WO1999052516A3 publication Critical patent/WO1999052516A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a medicament for use in providing cognitive enhancement in a mammalian subject, the medicament comprising an inhibitor substance which inhibits acylpeptide hydrolase (ACPH), and a physiologically acceptable carrier, excipient or diluent.
PCT/GB1999/001129 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function WO1999052516A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU34352/99A AU3435299A (en) 1998-04-15 1999-04-14 Improvements in or relating to protease inhibitors
CA002328360A CA2328360A1 (en) 1998-04-15 1999-04-14 Improvements in or relating to protease inhibitors
JP2000543126A JP2002511407A (en) 1998-04-15 1999-04-14 Improvements in or related to protease inhibitors
EP99915931A EP1077689A1 (en) 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9807931.2 1998-04-15
GBGB9807931.2A GB9807931D0 (en) 1998-04-15 1998-04-15 Improvements in or relating to protease inhibitors

Publications (2)

Publication Number Publication Date
WO1999052516A2 WO1999052516A2 (en) 1999-10-21
WO1999052516A3 true WO1999052516A3 (en) 1999-12-23

Family

ID=10830327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001129 WO1999052516A2 (en) 1998-04-15 1999-04-14 Acylpeptide protease inhibitors to enhance cognitive function

Country Status (6)

Country Link
EP (1) EP1077689A1 (en)
JP (1) JP2002511407A (en)
AU (1) AU3435299A (en)
CA (1) CA2328360A1 (en)
GB (1) GB9807931D0 (en)
WO (1) WO1999052516A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704145C (en) * 2006-10-31 2017-03-21 Roger A. Acey Butyrylcholinesterase inhibitors and their use in the treatment of neurodegenerative diseases
US9757399B2 (en) 2006-10-31 2017-09-12 Jal Therapeutics, Inc. Butyrylcholinesterase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024130A1 (en) * 1992-05-26 1993-12-09 Bayer Aktiengesellschaft Drug containing (-)-metriphonate
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024130A1 (en) * 1992-05-26 1993-12-09 Bayer Aktiengesellschaft Drug containing (-)-metriphonate
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BECKER ET AL: "double-blind, placebo-controlled study of metrifonate and acetylcholinesterase inhibitor for AD", ALZHEIMER'S DISEASE AND ASSOCIATED DISORDERS, vol. 10, no. 3, 1996, pages 124 - 131, XP002117918 *
MUCKE H.A.M.: "metrifonate . treatment on Alzheimer's disease, acetycholinesterase inhibitor", DRUGS OF THE FUTURE, vol. 23, no. 5, 1998, pages 491 - 497, XP002117919 *
VAN DER STAAY ET AL: "effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behaviour in young-adult rats", J. PHARMACOL. EXP. THERAP., vol. 278, 1996, pages 697 - 708, XP002117917 *

Also Published As

Publication number Publication date
CA2328360A1 (en) 1999-10-21
JP2002511407A (en) 2002-04-16
GB9807931D0 (en) 1998-06-10
WO1999052516A2 (en) 1999-10-21
AU3435299A (en) 1999-11-01
EP1077689A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
AU4236796A (en) Cysteine protease and serine protease inhibitors
CA2208018A1 (en) Sulfonamides
AU5414000A (en) Compounds
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
WO2003016335A3 (en) Irreversible cysteine protease inhibitors of legumain
AU4905097A (en) Thrombin inhibitors
HUP0203167A3 (en) Peptidic substances, their preparations and their use as complement protease inhibitors
HK1029936A1 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
MXPA04004372A (en) Heterocyclic derivatives of glycinamide and their medical use.
WO2003029293A3 (en) Modulators of notch ic protease activity for use in immunotherapy
MXPA04002001A (en) Method for thinning fruit.
AU6536200A (en) Proteases and protease inhibitors
HUP0002644A2 (en) Phartmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
IL125195A0 (en) Medical use of angiotensin converting enzyme inhibitor for treatment of dyspeptic symptoms
EP0635263A3 (en) Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue.
AU9624398A (en) Pyrrolopyrrolidine derivatives and their use as serine protease inhibitors
HK1039793A1 (en) Caspase-14, an apoptotic protease, uncleic acids encoding and methods of use
WO1999052516A3 (en) Acylpeptide protease inhibitors to enhance cognitive function
AU7133898A (en) Nanosized aspartyl protease inhibitors
GB9930768D0 (en) Composition
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2356001A (en) Surface treatment agent for laminated fabric
AU7928500A (en) Connection piece
CA2262582A1 (en) Hcg and derivatives as matrix metalloproteases inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999915931

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2328360

Country of ref document: CA

Ref country code: CA

Ref document number: 2328360

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09673371

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999915931

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999915931

Country of ref document: EP